BG106115A - Синергичните ефекти на амлодипин и аторвастатин метаболит като база за комбинирана терапия - Google Patents

Синергичните ефекти на амлодипин и аторвастатин метаболит като база за комбинирана терапия Download PDF

Info

Publication number
BG106115A
BG106115A BG106115A BG10611501A BG106115A BG 106115 A BG106115 A BG 106115A BG 106115 A BG106115 A BG 106115A BG 10611501 A BG10611501 A BG 10611501A BG 106115 A BG106115 A BG 106115A
Authority
BG
Bulgaria
Prior art keywords
pharmaceutical composition
amlodipine
organs
blood pressure
lipid
Prior art date
Application number
BG106115A
Other languages
Bulgarian (bg)
English (en)
Inventor
Preston Mason
Original Assignee
Preston Mason
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27494873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG106115(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Preston Mason filed Critical Preston Mason
Publication of BG106115A publication Critical patent/BG106115A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
BG106115A 1999-04-23 2001-11-16 Синергичните ефекти на амлодипин и аторвастатин метаболит като база за комбинирана терапия BG106115A (bg)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13066599P 1999-04-23 1999-04-23
US14530599P 1999-07-23 1999-07-23
US15112199P 1999-08-27 1999-08-27
US16659299P 1999-11-19 1999-11-19
PCT/US2000/010465 WO2000064443A1 (en) 1999-04-23 2000-04-18 Synergistic effects of amlodipine and atorvastatin

Publications (1)

Publication Number Publication Date
BG106115A true BG106115A (bg) 2002-11-29

Family

ID=27494873

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106115A BG106115A (bg) 1999-04-23 2001-11-16 Синергичните ефекти на амлодипин и аторвастатин метаболит като база за комбинирана терапия

Country Status (30)

Country Link
EP (1) EP1173172B1 (de)
JP (1) JP2002542289A (de)
KR (1) KR20020024581A (de)
CN (1) CN1351492A (de)
AP (1) AP2001002324A0 (de)
AT (1) ATE314846T1 (de)
AU (1) AU4647000A (de)
BG (1) BG106115A (de)
BR (1) BR0010689A (de)
CA (1) CA2370639A1 (de)
CZ (1) CZ20013793A3 (de)
DE (1) DE60025344T2 (de)
DK (1) DK1173172T3 (de)
EA (1) EA004435B1 (de)
EE (1) EE200100555A (de)
ES (1) ES2256005T3 (de)
HK (1) HK1043741A1 (de)
HU (1) HUP0201016A3 (de)
IL (1) IL146085A0 (de)
IS (1) IS6118A (de)
NO (1) NO20015128L (de)
OA (1) OA11870A (de)
PE (1) PE20010055A1 (de)
PL (1) PL351408A1 (de)
PT (1) PT1173172E (de)
SK (1) SK15382001A3 (de)
SV (1) SV2002000058A (de)
TN (1) TNSN00085A1 (de)
UY (1) UY26118A1 (de)
WO (1) WO2000064443A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
CN100430057C (zh) * 2005-04-08 2008-11-05 石药集团中奇制药技术（石家庄）有限公司 左旋氨氯地平和阿托伐他汀的药物组合物
KR101467110B1 (ko) * 2013-08-01 2014-11-28 한국방송공사 코로나링을 구비한 지선애자

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.

Also Published As

Publication number Publication date
OA11870A (en) 2006-03-27
JP2002542289A (ja) 2002-12-10
EP1173172B1 (de) 2006-01-04
EE200100555A (et) 2002-12-16
NO20015128D0 (no) 2001-10-19
HUP0201016A3 (en) 2003-03-28
DK1173172T3 (da) 2006-05-15
CZ20013793A3 (cs) 2002-05-15
AP2001002324A0 (en) 2001-12-31
ES2256005T3 (es) 2006-07-16
PL351408A1 (en) 2003-04-22
DE60025344T2 (de) 2006-09-28
AU4647000A (en) 2000-11-10
CA2370639A1 (en) 2000-11-02
UY26118A1 (es) 2001-03-16
KR20020024581A (ko) 2002-03-30
SK15382001A3 (sk) 2002-05-09
EA200101112A1 (ru) 2002-06-27
SV2002000058A (es) 2002-02-05
HK1043741A1 (zh) 2002-09-27
CN1351492A (zh) 2002-05-29
PT1173172E (pt) 2006-05-31
IS6118A (is) 2001-10-19
NO20015128L (no) 2001-12-20
EA004435B1 (ru) 2004-04-29
HUP0201016A2 (hu) 2002-07-29
WO2000064443A1 (en) 2000-11-02
PE20010055A1 (es) 2001-01-30
IL146085A0 (en) 2002-07-25
ATE314846T1 (de) 2006-02-15
TNSN00085A1 (fr) 2005-11-10
BR0010689A (pt) 2002-02-19
DE60025344D1 (de) 2006-03-30
EP1173172A1 (de) 2002-01-23
EP1173172A4 (de) 2002-08-07
WO2000064443A9 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
US20070037860A1 (en) Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
KR100586754B1 (ko) 지단백질 산화의 억제
Napoli et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension
Prasad C‐reactive protein (CRP)‐lowering agents
AU2002211452B2 (en) Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases
KR101494067B1 (ko) 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
KR100200467B1 (ko) 콜레스테롤 저하제 및 ace 억제제로 이루어진 아테롬성 동맥경화증의 예방, 안정화 또는 경감용 조성물
Golper et al. Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria
US20020052394A1 (en) Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release
Jorge et al. Rapid reversal of endothelial dysfunction in hypercholesterolaemic rabbits treated with simvastatin and pravastatin
BG106115A (bg) Синергичните ефекти на амлодипин и аторвастатин метаболит като база за комбинирана терапия
Illingworth New horizons in combination drug therapy for hypercholesterolemia
Lapenna et al. Antioxidant activity of amiodarone on human lipoprotein oxidation
JP2002542289A5 (de)
Fleckenstein-Grün et al. Role of calcium in arteriosclerosis—experimental evaluation of antiarteriosclerotic potencies of Ca antagonists
MXPA01010694A (en) Synergistic effects of amlodipine and atorvastatin
MXPA00003200A (en) Inhibtion of lipoprotein oxidation
TSAI et al. Comparison of pravastatin alone and with cholestyramine in the treatment of hypercholesterolemia